Researchers found a suicide attempt rate of 12.0% in first-episode, drug-naive inpatients.
The findings support second generation long-acting injectable antipsychotic drug use as early treatment option to increase treatment adherence and to decrease the risk of relapse, hospitalization, and deteriorating social functions.
WSE treatment may be useful in addressing symptom exacerbation in schizophrenia and schizoaffective disorder.
Investigators examined factors that may improve employment in patients with schizophrenia.
Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.
These results may be helpful for clinicians when considering the effects of antipsychotic intervention on patient high-density lipoprotein cholesterol levels.
Inhalant and other substance use during adolescence are increasingly associated with many adverse health and psychosocial outcomes.
These data have implications for the efficacy of the US military healthcare system as a whole in treating psychosis in service members.
FDA Approval of Medication With a Digital Monitoring System: Major Breakthrough or "Brave New World"?July 23, 2018
Abilify MyCite adds a digital sensor to the medication aripiprazole. The sensor, an ingestible event marker, is activated by contact with stomach acids and transmits a signal to a skin patch the patient wears, which then transmits to an app.
As psychosis and substance use disorder comorbidity can make oral medication adherence difficult, long-acting injectable agents may be an effective therapeutic alternative in patients in this demographic.
Each of the studied brain modalities could be classified as "gray matter abnormalities" or "white matter disruptions" and may be significant in the pathology of schizophrenia.
This study created a validated model for determining brain age and brain age gap, which then can be used to predict early-onset psychosis in younger clinically high-risk adolescents who exhibit prodromal symptoms.
The findings of this study contribute to the understanding of the neurodevelopmental cognitive vulnerability in middle childhood for the children of people with either schizophrenia or bipolar disorder.
These data suggest that aripiprazole can be safely used in premenopausal women to treat elevated prolactin levels and prolactin-related adverse effects.
Atypical antipsychotic use was associated with a higher risk for cardiovascular events among publicly insured youth in the US.
Prior to this approval, the Aristada initiation regimen consisted of taking oral aripiprazole for 21 consecutive days starting with the first Aristada dose.
The main message from the present paper is to carefully identify the psychotic patients that do not improve from their debilitating depressive symptoms during an acute phase of psychosis.
Results of this meta-analysis highlight the potential advantages of long-acting injectable antipsychotics vs oral antipsychotics in treating schizophrenia.
As antipsychotic medications are vital to the effective management of severe psychiatric disorders, investigators sought to examine reasons for medication nonadherence in patients with schizophrenia, bipolar disorders, and other psychotic disorders.
In considering patients with schizophrenia for cognitive remediation, comorbid OCD must be taken into account.
These results indicate that impaired visual integration in patients with schizophrenia may more broadly be a feature of psychosis, rather than specifically of schizophrenia.
Researchers hope that in demonstrating the potential efficacy of MIN-101, they may improve the pharmacotherapy options available to patients with schizophrenia.
A substantial proportion of these individuals diagnosed with HIV, psychiatric disorders, and substance use disorders are out of care and urgently require intervention.
The superior benefit provided by early intervention services for schizophrenia could be cost-effective, and the researchers call for widespread implementation and funding of early intervention services in the United States and globally.
Researchers conducted a systematic literature review to identify cohort studies reporting the standardized incidence ratio for the risk of breast cancer in women with schizophrenia compared with the general population.
Investigators examined the long-term efficacy of deutetrabenazine measured by Abnormal Involuntary Movement Scale, Clinical Global Impressions Scale, and Patients' Global Impression of Change Scale in real-word clinical practice settings.
Adjunctive raloxifene may reduce negative symptom scores in women with schizophrenia or schizoaffective disorder.
The phase 3 study assessed the antipsychotic efficacy and safety of ALKS 3831 in patients with acute exacerbations of schizophrenia.
These data may be helpful in titrating care for those with schizotypal disorder and comorbid substance abuse disorders to mitigate the risk for conversion to schizophrenia.
Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Healthcare Community Should Favor More Restrictive Alcohol Policies
- How to Respond to a Patient's Request for Prayer: A Clinician's Dilemma
- Major Barriers to Useful Risk Prediction Must Be Overcome to Reach the Full Potential of Big Data
- ACA Coverage Gains Include Workers Without Insurance
- Steps Provided for Discharging Patients From Practice